GE HealthCare Technologies Inc. reported its financial results for the third quarter ended September 30, 2026, and announced changes to its leadership structure. The company reported total revenues of $5.5 billion for the quarter, representing a 7.2% increase compared to the prior year period. Organic revenue growth was reported at 6.2%, with growth observed across all segments.
On the bottom line, net income attributable to GE HealthCare was $615 million for the third quarter, compared to $446 million in the prior year. Diluted earnings per share (EPS) were $1.36, up from $0.98 in the prior year. The company also reported an adjusted earnings before interest and taxes (EBIT) margin of 16.6% and free cash flow of $793 million for the quarter.
In terms of backlog, the company reported total orders up 4.0% organically and a book-to-bill ratio of 1.03 times. The backlog as of September 30, 2026, was $23.7 billion.
GE HealthCare announced that Jeannette Bankes will resign as President and CEO of the Patient Care Solutions segment, effective November 15, 2026. She is leaving to assume a CEO role at a publicly traded company. Neal Sandy, currently head of PCS Product Strategy and Management, will assume the role of President and CEO of PCS on November 16, 2026.
The company also provided updated guidance for the full year 2026. For organic revenue growth, the company raised its guidance to a range of 4.0% to 4.0%. Adjusted EPS guidance was raised to a range of $4.95 to $5.05, and free cash flow guidance was raised to $1.6 billion or greater.
Additionally, GE HealthCare announced plans to acquire SOFIE Biosciences from Trilantic North America for a purchase price of $945 million, to be paid in cash. The transaction is expected to close in the first half of 2027, subject to regulatory approvals.
